NAV
$58.46
AUM
$55.8M
Expense Ratio
-
Dividend Yield
1.11%
Beta
1.62
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +28.48% | +20.25% | +32.58% | +70.56% | +6.99% | -9.62% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | GH | Guardant Health Inc | 5.59% |
| 2 | ILMN | Illumina Inc | 4.82% |
| 3 | NTRA | Natera Inc | 4.15% |
| 4 | BMRN | BioMarin Pharmaceutical Inc | 4.08% |
| 5 | ARWR | Arrowhead Pharmaceuticals Inc | 4.07% |
| 6 | LEGN | Legend Biotech Corp ADR | 4.04% |
| 7 | PRAX | Praxis Precision Medicines Inc Ordinary Shares | 4.01% |
| 8 | TWST | Twist Bioscience Corp | 3.96% |
| 9 | VRTX | Vertex Pharmaceuticals Inc | 3.95% |
| 10 | CRSP | CRISPR Therapeutics AG | 3.84% |
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
Inception Date: 2019-04-05